budesonide / Generic mfg. - LARVOL DELTA

APPLICATION OF TRF-BUDESONIDE (NEFECON) IN THE TREATMENT OF PEDIATRIC PATIENT WITH IGA NEPHROPATHY: A CASE REPORT (ISN-WCN 2026) - "Introduction Immunoglobulin A nephropathy (IgAN) is one of the most common primary glomerular diseases in children and adolescents, with 20% of affected children progressing to end-stage kidney disease (ESKD) within 20 years of diagnosis. A 6-month follow-up confirmed sustained benefits with Benazepril alone. These findings suggest Nefecon may be a safe and effective option for pediatric IgAN, but further large-scale studies are needed to confirm long-term safety, optimal dosing, and efficacy across diverse pediatric populations."

Case report • Clinical • Acne Vulgaris • Gastroenterology • Gastrointestinal Disorder • Glomerulonephritis • Human Immunodeficiency Virus • IgA Nephropathy • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pediatrics • Renal Disease

BUDESONIDE MODULATES B- AND T-CELL IMMUNITY IN PEYER'S PATCHES: IMPLICATIONS FOR IGA NEPHROPATHY (ISN-WCN 2026) - "These findings support the localized action of nefecon for the treatment of IgAN. Further studies using transcriptomic profiling and disease models are warranted to elucidate budesonide's immunological mechanisms in PPs.I have potential conflict of interest to disclose.Funding/commercial Support: Calliditas TherapeuticsI did not use generative AI and AI-assisted technologies in the writing process."

Glomerulonephritis • IgA Nephropathy • Renal Disease • CASP3 • CD69 • CD86 • FAS • FOXP3 • IFNG • IL10 • IL2RA • SDC1

RENOPROTECTIVE EFFICACY AND SAFETY PROFILE OF TARGETED-RELEASE BUDESONIDE IN IGA NEPHROPATHY: A SYSTEMATIC REVIEW AND META-ANALYSIS (ISN-WCN 2026) - "Although TEAEs and treatment discontinuations were more common, severe adverse events were not significantly increased. These findings support TRF budesonide as an effective and generally well-tolerated therapy for IgAN, with further studies needed to optimize patient selection and long-term safety outcomes."

Retrospective data • Review • Glomerulonephritis • IgA Nephropathy • Lupus Nephritis • Renal Disease

THE CREATION AND INITIAL DEMOGRAPHICS OF THE PERFORM™ PATIENT REGISTRY: A NOVEL REAL-WORLD REGISTRY OF PATIENTS TREATED FOR IGA NEPHROPATHY IN THE UNITED STATES (ISN-WCN 2026) - "To address this need, the PERFORM™ Patient Registry (PPR) has been created to assess the longitudinal disease characteristics, healthcare utilization, clinical management, and treatment utilization patterns of patients treated with delayed-release budesonide (Tarpeyo®) for IgAN in the United States (US). Among participants, 61% were male, 11% were Hispanic/Latino, 72% were White, 4% were Black/African American, 12% were Asian, and 10% were of other races.Conclusion While enrollment is ongoing, the current PPR population comprises a varied cohort of patients treated with Tarpeyo® for IgAN. This registry will allow for further understanding of IgAN management and outcomes for patients treated with Tarpeyo® for IgAN.This abstract was also submitted for the American Society of Nephrology Kidney Week 2025 congress.I have potential conflict of interest to disclose.Funding/commercial support: Calliditas TherapeuticsI did not use generative AI and AI-assisted..."

Clinical • Real-world • Real-world evidence • Glomerulonephritis • IgA Nephropathy • Renal Disease

IMPACT OF TREATMENT WITH NEFECON ON SERUM BIOMARKERS OF GUT-ASSOCIATED LYMPHOID TISSUE FUNCTION IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY FROM THE PHASE 3 NEFIGARD TRIAL (ISN-WCN 2026) - "Nefecon is a targeted-release budesonide formulation that delivers high, localized concentrations of budesonide to the terminal ileum of the GALT, reducing the production of pathogenic forms of IgA. We previously reported that in these same participants, treatment with nefecon significantly reduced serum levels of galactose-deficient IgA1 (Gd-IgA1), anti–Gd-IgA1 immunoglobulin G (IgG) and IgA-IgG immune complexes. Collectively these data support a disease-modifying role for nefecon in the treatment of IgAN.I have potential conflict of interest to disclose.Funding/commercial support: Calliditas TherapeuticsI did not use generative AI and AI-assisted technologies in the writing process."

Biomarker • Clinical • P3 data • Glomerulonephritis • IgA Nephropathy • Renal Disease • CCL11 • CCL19 • CCL20 • CD27 • CXCL13 • CXCL5 • CXCL6 • IL18BP

NOVEL THERAPEUTIC APPROACH FOR SEVERE IGA NEPHROPATHY BY MP PULSE AND SVF/MSC (ISN-WCN 2026) - "Introduction Up to date there is no specific treatment method for severe IgAN,but trying ARB,omega-3,MRA,complement inhibitos,budesonide,endothelin inhibitors,complement inhibitors,SGLT2 inhibitors etc but eventually fall into ESRD...Follow up renal biopsy showed disppearance of EDD,reduced mesangial proliferation,improved epithelial foot process fusion and disappearance of IgA deposition by IF microscopy in group A & B.Conclusion MP pulse therapy and autologous SVF/MSC have showed promising results without signicant side-effects in severe IgAN. Although further longterm and large number studies are mandatory."

Chronic Kidney Disease • Glomerulonephritis • IgA Nephropathy • Renal Disease

CLINICAL EFFICACY OBSERVATION OF BUDESONIDE ENTERIC-COATED CAPSULES IN THE TREATMENT OF 53 CASES OF IGA NEPHROPATHY: AN ANALYSIS BASED ON 6-MONTH FOLLOW-UP INDICATORS (ISN-WCN 2026) - "UACR decreased from the baseline mean of 888.80 mg/g to approximately 500 mg/g; 24h UPro decreased from 1.50 mg/24h to near the lower limit of the normal range; and URBC decreased from 83.87 /uL to near the normal range (0-5 /uL).Conclusion Budesonide enteric-coated capsules can effectively maintain the stability of renal function in patients with IgA nephropathy, significantly improve urine indicators, and have good safety. It is suitable as an important option for clinical treatment."

Clinical • Glomerulonephritis • IgA Nephropathy • Renal Disease

REAL WORLD DATA OF SHORT-TERM EFFICACY OF BUDESONIDE ENTERIC-COATED CAPSULES IN TREATING PRIMARY IGA NEPHROPATHY FROM A SINGLE CENTER (ISN-WCN 2026) - "As to the renal function, the eGFR increased by 5.23% compared to baseline by the 8th week (P=0.105) and finally increased by 9.79% at 24th week with an upward trend (P=0.171).Conclusion Budesonide enteric-coated capsules demonstrated an early significant reduction in proteinuria with mild increased eGFR at the 8th week of treatment in primary IgA nephropathy. The early efficacy remained significant till the 24th weeks, suggesting the effectiveness in short-term treatment."

Clinical • Real-world • Real-world evidence • Glomerulonephritis • IgA Nephropathy • Renal Disease

Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial (ISN-WCN 2026) - No abstract available

Clinical • Late-breaking abstract • P2/3 data • Glomerulonephritis • IgA Nephropathy • Renal Disease

Dose-dependent effects of Alveofact with and without steroids on neutrophil extracellular traps in neonatal respiratory distress syndrome. (PubMed, Pediatr Res) - P1 | "A combination of 100 mg/kg Alveofact with budesonide effectively attenuates neutrophil-driven inflammation and oxidative stress in neonatal RDS. The study was registered on the Clinical Trial Registration Site (ID: NCT06367881, first submitted 2024-04-07)."

Journal • Acute Respiratory Distress Syndrome • Inflammation • Respiratory Diseases

Efficacy of current therapeutic strategies for immune checkpoint inhibitor-related esophagitis. (PubMed, Ann Gastroenterol) - "No significant differences in clinical improvement, ICI resumption or all-cause mortality were noted between the corticosteroid and non-corticosteroid groups. Our findings showed faster clinical improvement with steroids, while PPIs demonstrated no significant effectiveness."

Checkpoint inhibition • Journal • Gastrointestinal Disorder • Oncology

Callicarpa nudiflora-derived extracellular vesicle-like particles loaded with budesonide enhance the treatment of ulcerative colitis by regulating M1/M2 macrophage polarization. (PubMed, Biomater Adv) - "Moreover, CN-EVLP could modulate macrophage M1/M2 polarization, further enhancing its anti-inflammatory efficacy. Thus, CN-EVLP shows promising potential as a novel nanomedicine delivery vehicle for UC therapy."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL6 • TNFA

Collagenous sprue across five decades (1970-2025): a systematic review. (PubMed, Scand J Gastroenterol) - "Mortality among patients with known vital status was 23% (12/53). CS is profoundly morbid but frequently improves with early recognition, medication review and withdrawal, aggressive nutritional support and steroid-based therapy, although relapse and mortality remain substantial."

Journal • Celiac Disease • Gastrointestinal Disorder

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: University of Utah | Suspended ➔ Recruiting

Enrollment open • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • Plasma Cell Leukemia • Transplantation • CD34

Therapeutic Efficacy of Intratracheal Budesonide Delivered with Surfactant in Preterm Infants: A Meta-analysis with Subgroup Evaluation of Extremely Preterm and Extremely Low Birth Weight Neonates (PAS 2026) - No abstract available

Prematurity • Retrospective data • Surfactant

Impact of Time-Sensitive Recruitment on Representativeness in The Budesonide in Babies Randomized Controlled Trial (PAS 2026) - No abstract available

Clinical

Health and Neurodevelopmental Outcomes at 2 Years of Extremely Preterm Infants Enrolled in the International PLUSS Trial of Intratracheal Budesonide (PAS 2026) - No abstract available

Neurodevelopmental • Prematurity

The Efficacy of Surfactant (curosurf) as Vehicle for Budesonide Delivery to the Lung. (PAS 2026) - No abstract available

Clinical • Surfactant

Surface hydrophobicity and rigidity determines protein corona on orally delivered nanoparticles treating colitis. (PubMed, Nat Commun) - "We show that high surface hydrophobicity boosts overall protein adsorption, leading to improved colon macrophage delivery and therapeutic effect when loaded with budesonide...Consequently, high rigidity nanoparticles more effectively attenuates the inflammatory state and restores the immune homeostasis in male rats with colitis. Our work develops a rational strategy of manipulating protein corona formation through physicochemical properties for efficient oral drug delivery, holding broad promise for diverse nanocarriers and pathologies."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • S100A8

Target-Release Budesonide in IgA Nephropathy: Rapid Proteinuria Reduction with Notable Steroid-Related Toxicity in Real-World Practice (UKKW 2026) - "Target-release formulation (TRF) budesonide (Kinpeygo®) acts on Peyer’s patches to reduce mucosal immune activation, offering a gut-targeted approach with limited systemic exposure. In this real-world cohort, TRF-budesonide produced a rapid and sustained fall in proteinuria with stable or improved kidney function. However, 20% of patients discontinued due to steroid-related toxicity, including metabolic complications. These findings highlight the importance of careful patient selection and close monitoring, even with gut-targeted steroid therapy."

Clinical • Real-world • Real-world evidence • Diabetes • Diabetic Nephropathy • Glomerulonephritis • IgA Nephropathy • Lupus Nephritis • Metabolic Disorders • Nephrology • Renal Disease

Evaluation of side effects and evidence of systemic absorption in patients with IgA Nephropathy treated with targeted-release budesonide (Kinpeygo) (UKKW 2026) - "Budesonide is a highly potent steroid; 16mg is equivalent to oral prednisolone 213mg1. Future work to evaluate the longer-term effects of TRf-budesonide in different ethnic populations, including effects on the hypothalamic-pituitary-adrenal axis and adverse effects is required. References: 1: Equivalent dosage of commonly used steroids (Journal of Allergy and Clinical Immunology): https://www.jacionline.org/cms/10.1016/j.jaci.2015.07.046/attachment/9e6d93c6-b64b- 4468-8cf5-38a0e9b551e9/mmc2.pdf"

Adverse events • Clinical • Acne Vulgaris • Glomerulonephritis • Hematological Malignancies • IgA Nephropathy • Immunology • Infectious Disease • Lupus Nephritis • Lymphoma • Metabolic Disorders • Nephrology • Pneumonia • Renal Disease • Respiratory Diseases • Retinal Disorders • CYP3A4

Collagenous Gastritis in the Adult Population: A 13-Year Review of Histologic Findings and Follow-Up Biopsies (USCAP 2026) - "Initial treatments included PPIs (38.5%), budesonide (34.6%), surveillance (26.9%), and discontinuation of offending agents (19.2%)... In CG, atrophy was common and associated with pronounced LP inflammation. CG persists in follow-up biopsies except for the medication-related group. Endoscopic classification based on nodularity has questionable utility."

Biopsy • Clinical • Review • Celiac Disease • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation

INCIDENCE, RISK FACTORS AND OUTCOMES OF AVASCULAR NECROSIS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS DEVELOPING GRAFT-VERSUS-HOST DISEASE (EBMT 2026) - "All patients had hip involvement with median ARCO stage II; 4 had shoulder and 1 had wrist involvement(median number of joints involved: 2,range:1-4).Twelve AVN patients required vitamin D supplementation at diagnosis of AVN, and 13 received bisphosphonates(alendronate:11, zoledronate:2)...AVN cases received higher starting dose of systemic steroids for acute GVHD(median:2.19 vs 1.19 mg/kg prednisolone equivalents, p=0.016), but there were no differences in steroid therapy duration, steroid-refractoriness, or use of maintenance prednisolone and oral budesonide... Symptomatic AVN incidence among ASCT recipients who developed GVHD was 6.4%, with 57% requiring surgery. Higher pre-ASCT steroid exposure, higher initial steroid dose for acute GVHD, higher CD3+ cell dose, and pre-ASCT vitamin D deficiency were potentially modifiable risk factors for AVN."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Orthopedics • Transplantation

6-mercaptopurine and tofacitinib alter microbial protein expression but not composition in fecal microbiota incubations from Crohn's disease patients. (PubMed, BMC Biol) - "Tofacitinib and especially 6-MP significantly affect microbial function, but barely microbial composition in vitro. These drug-induced functional changes may subsequently influence host physiology and potentially inflammation in CD. Our findings emphasize the relevance to include functional microbial studies when investigating drug-microbiota interactions. Further research is needed to elucidate the impact of 6-MP-induced microbial alterations on intestinal physiology and inflammation in CD."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

INCIDENCE, RISK FACTORS AND OUTCOMES OF AVASCULAR NECROSIS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS DEVELOPING GRAFT-VERSUS-HOST DISEASE (EBMT 2026) - "All patients had hip involvement with median ARCO stage II; 4 had shoulder and 1 had wrist involvement(median number of joints involved: 2,range:1-4).Twelve AVN patients required vitamin D supplementation at diagnosis of AVN, and 13 received bisphosphonates(alendronate:11, zoledronate:2)...AVN cases received higher starting dose of systemic steroids for acute GVHD(median:2.19 vs 1.19 mg/kg prednisolone equivalents, p=0.016), but there were no differences in steroid therapy duration, steroid-refractoriness, or use of maintenance prednisolone and oral budesonide... Symptomatic AVN incidence among ASCT recipients who developed GVHD was 6.4%, with 57% requiring surgery. Higher pre-ASCT steroid exposure, higher initial steroid dose for acute GVHD, higher CD3+ cell dose, and pre-ASCT vitamin D deficiency were potentially modifiable risk factors for AVN."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Orthopedics • Transplantation